海王生物：股票交易异常波动

Core Viewpoint - The stock price of Haiwang Biological experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days from November 26 to November 27, 2025 [1] Group 1: Company Response - The company conducted an investigation regarding the stock price fluctuation and confirmed that there were no corrections or supplements needed for previously disclosed information [1] - The company stated that there have been no significant changes in its production and operational conditions, nor in the internal and external business environment [1] - The company, its controlling shareholders, and actual controllers confirmed that there are no undisclosed significant matters or major events in the planning stage [1] Group 2: Trading Activity - During the period of abnormal stock fluctuation, the controlling shareholders and actual controllers, along with their concerted actions, did not engage in buying or selling the company's stock [1] - The company affirmed that it has not violated any fair information disclosure regulations [1] - The board of directors confirmed that there are no undisclosed matters that could significantly impact the stock trading price [1]